Early "male lumpectomy" study could boost the use of focal cryoablation therapy
This article was originally published in Clinica
Executive Summary
Potentially pushing focal cryoablation therapy into an additional US patient base of 180,000, a study has shown that the therapy can be used to successfully treat 80% of prostate cancer patients - where it is currently a niche treatment. The study, by the Celebration Health/Florida Hospital in Orlando, found that the therapy preserved potency in a majority of patients and limited incontinence problems, "without compromising cancer control". The authors claimed that the therapy will "fill the gap" between watchful waiting and "radical" whole irradiation treatments.